← Back to Search

Other

TNP-2092 for Prosthetic Joint Infections

Phase 1
Waitlist Available
Research Sponsored by TenNor Therapeutics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or females, 18 years of age or older
Capable of giving signed informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day2, day7, day14
Awards & highlights

Study Summary

This trial will study how TNP-2092 moves into different tissues in people having either a hip or knee replacement surgery.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day2, day7, day14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day2, day7, day14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Concentration of TNP-2092 in bone
Concentration of TNP-2092 in synovial fluid
Secondary outcome measures
Plasma PK of a single IV dose of TNP-2092
Rate of adverse event with TNP-2092

Side effects data

From 2020 Phase 2 trial • 120 Patients • NCT03964493
15%
Nausea
9%
Cellulitis
8%
Vomiting
3%
Wound infection
1%
MRSA bacteremia and worsening cellulitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
TNP-2092
Vancomycin

Trial Design

1Treatment groups
Experimental Treatment
Group I: TNP-2092 300mg IVExperimental Treatment1 Intervention
TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TNP-2092
2016
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

TenNor Therapeutics LimitedLead Sponsor
2 Previous Clinical Trials
126 Total Patients Enrolled

Frequently Asked Questions

~3 spots leftby Mar 2025